Table 3.
Induced models of B-cell lymphoma. (m): murine origin; (h): human origin; (i): syngeneic models; (ii): syngeneic models with murine tumor cells engineered to express human antigens; (iii): xenogenic models; (iv): humanized models; CLL: chronic lymphocytic leukemia; DLBCL: diffuse large B-cell lymphoma; MALT: mucosa associated lymphatic tissue; n.d.: not determined; PCL: primary cerebral lymphoma; PCNSL: primary central nervous system lymphoma; PIOL: primary intraocular lymphoma; SCID: severe combined immune deficiency.
| Injection site | Name | Lymphoma model | Recipient mice | Major reference | ||
|---|---|---|---|---|---|---|
| Strain (haplotype) | MHC compatibility | Immune status | ||||
| Intravenous | B6 spontaneous model (m) | High-grade B lymphoma | C57Bl/6 (H-2b) | Syngeneic (i) | Immunocompetent | [51] |
| Pi-BCL1 (m) | DLBCL | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [52] | |
| 38C13 (m) | Non-Hodgkin lymphoma | C3H/HeN (H-2k) | Syngeneic (i) | Immunocompetent | [53] | |
| FL5.12 transfected by Bcl2 (m) | Non-Hodgkin lymphoma | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [42] | |
| A20 (m) | DLBCL | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [54] | |
| 4TOO (m) | n.d. | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [55] | |
| BCL1 (m) | CLL | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [56] | |
| 38C13 Her2/neu (m) | Non-Hodgkin lymphoma | C3H/HeN (H-2k) | Syngeneic (ii) | Immunocompetent | [40] | |
| Z138 (h) | Human mantle cell lymphoma | SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [57] | |
| BJAB (h) | Burkitt lymphoma | SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [58] | |
| SU-DHL-4 (h) | DLBCL | SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [59] | |
|
| ||||||
| Intrasplenic | A20 (m) | DLBCL | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [60] |
| A20.IIA-GFP (m) | DLBCL | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [50] | |
|
| ||||||
| Intraperitoneal | CH44 (m) | Non-Hodgkin lymphoma | B10.H-2aH-4bp/Wts | Syngeneic (i) | Immunocompetent | [34] |
| BCL1 (m) | DLBCL | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [53] | |
| 38C13 (m) | Non-Hodgkin lymphoma | C3H/HeN (H-2k) | Syngeneic (i) | Immunocompetent | [53] | |
| Tonsillar lymphocytes and EBV infection (h) | Viro-induced lymphoma | BNXhum (humanized) | Allogenic (iv) | Immunocompetent | [61] | |
|
| ||||||
| Subcutaneous | LY-ar or LY-as (m) | n.d. | C3Hf/kam (H-2k) | Syngeneic (i) | Immunocompetent | [37] |
| S11 (m) | Burkitt lymphoma | BALB/c nude (H-2d) | Syngeneic (i) | T-cell deficiency | [62] | |
| LMycSN-p53null (m) | Non-Hodgkin lymphoma | C57Bl/6 (H-2b) | Syngeneic (i) | Immunocompetent | [18] | |
| A20 (m) | DLBCL | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [63] | |
| 38C13 Her2/neu (m) | Non-Hodgkin lymphoma | C3H/HeN (H-2k) | Syngeneic (ii) | Immunocompetent | [40] | |
| Myc5-M5 (m) | n.d. | SCID mice (H-2d) | Allogenic | Immunodeficient | [17] | |
| Splenic Hodgkin lymphoma cells (h) | Hodgkin disease | Nude mice (H-2b) | Xenogenic (iii) | T-cell deficiency | [64] | |
| Human hodgkin cell line (h) | Hodgkin disease | SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [47] | |
| Ramos (h) | Burkitt lymphoma | SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [58] | |
| BJAB (h) | Burkitt lymphoma | SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [58] | |
| SC-1 (h) | Follicular lymphoma | SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [58] | |
| DoHH-2 (h) | Follicular lymphoma | SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [58] | |
| SuDHL-4 (h) | DLBCL | C.B-17 SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [65] | |
| Granta 519 (h) | Mantle cell lymphoma | C.B-17 SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [65] | |
| HKBML (h) | Brain DLBCL | C.B-17 SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [46] | |
| Daudi (h) | Burkitt lymphoma | SCID/beige mice (H-2d) | Xenogenic (iv) | Partially rebuilt | [66] | |
| Jijoye (h) | Burkitt lymphoma | SCID/beige mice (H-2d) | Xenogenic (iv) | Partially rebuilt | [66] | |
|
| ||||||
| Intramuscular | MSV-MuLV-M induced | Waldenstrom's macroglobulinemia | C57Bl/6 (H-2b) | Syngeneic | Immunocompetent | [67] |
| Mouse lymphosarcoma cell line (m) | Non-Hodgkin lymphosarcoma | CBA (H-2k) | Syngeneic (i) | Immunocompetent | [41] | |
|
| ||||||
| Stomach | Helicobacter felis | MALT lymphoma | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [48] |
|
| ||||||
| Intracerebral | A20.IIA-GFP (m) | PCL (PCNSL) | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [50] |
| 38C13 CD20+ (m) | PCL (PCNSL) | C3H/HeN (H-2k) | Syngeneic (ii) | Immunocompetent | [68] | |
| Raji (h) | PCL (PCNSL) | Nude mice (H-2b) | Xenogenic (iii) | T-cell deficiency | [69] | |
| Patient's cells (h) | PCL (PCNSL) | Nude mice (H-2b) | Xenogenic (iii) | T-cell deficiency | [70] | |
| MC116 (h) | PCL (PCNSL) | Nude rats (RT1u) | Xenogenic (iii) | Immunodeficient | [71] | |
|
| ||||||
| Cisterna magna | L1210 (m) | Leptomeningeal metastases | DBA/2 (H-2d) | Syngeneic (i) | Immunocompetent | [72] |
|
| ||||||
| Intraocular | A20.IIA-GFP (m) | PIOL | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [45] |
| 38C13 CD20+ (m) | PIOL | C3H/HeN (H-2k) | Syngeneic (ii) | Immunocompetent | [68] | |
| CA46 (h) | PIOL | SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [73] | |